These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12415691)

  • 41. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.
    Chiu HC; Chou DL; Huang CT; Lin WH; Lien TW; Yen KJ; Hsu JT
    Biochem Pharmacol; 2011 Jun; 81(11):1263-70. PubMed ID: 21406185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of receptor tyrosine kinase inhibitor A47 on estrogen and growth factor-dependent breast cancer cell proliferation and apoptosis in vitro.
    Turbov JM; Twaddle GM; Yang X; Liu NM; Murthy S
    J Surg Oncol; 2002 Jan; 79(1):17-29. PubMed ID: 11754373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
    Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EGFR plays a pivotal role in the regulation of polyamine-dependent apoptosis in intestinal epithelial cells.
    Ray RM; Bhattacharya S; Johnson LR
    Cell Signal; 2007 Dec; 19(12):2519-27. PubMed ID: 17825525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidermal growth factor receptor (EGFR) regulates mechanical ventilation-induced lung injury in mice.
    Bierman A; Yerrapureddy A; Reddy NM; Hassoun PM; Reddy SP
    Transl Res; 2008 Dec; 152(6):265-72. PubMed ID: 19059161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins.
    Krystal GW; Carlson P; Litz J
    Cancer Res; 1997 Jun; 57(11):2203-8. PubMed ID: 9187122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
    Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
    Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

  • 53. YXQ-EQ Induces Apoptosis and Inhibits Signaling Pathways Important for Metastasis in Non-Small Cell Lung Carcinoma Cells.
    Yan X; Shen H; Jiang H; Hu D; Wang J; Wu X
    Cell Physiol Biochem; 2018; 49(3):911-919. PubMed ID: 30184531
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The mitogen-activated protein kinase cascade mediates neurotrophic effect of epidermal growth factor in cultured rat hippocampal neurons.
    Abe K; Saito H
    Neurosci Lett; 2000 Mar; 282(1-2):89-92. PubMed ID: 10713403
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Further evidence for the involvement of insulin receptor substrates in epidermal growth factor-induced activation of phosphatidylinositol 3-kinase.
    Fujioka T; Kim JH; Adachi H; Saito K; Tsujimoto M; Yokoyama S; Ui M
    Eur J Biochem; 2001 Aug; 268(15):4158-68. PubMed ID: 11488908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. R2-8018 reduces the proliferation and migration of non-small cell lung cancer cells by disturbing transactivation between M3R and EGFR.
    Lan L; Wang H; Yang R; Liu F; Bi Q; Wang S; Wei X; Yan H; Su R
    Life Sci; 2019 Oct; 234():116742. PubMed ID: 31401315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells.
    Kitazaki T; Soda H; Doi S; Nakano H; Nakamura Y; Kohno S
    Lung Cancer; 2005 Oct; 50(1):19-24. PubMed ID: 16009452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.